Sandoz
Manufacturing · Switzerland · 22,633 Employees
View Company Info for Free
About
Headquarters
Forum 1 Novartis Campus, Basel, Basel-City, 405...Phone Number
+41 613241111Website
www.sandoz.comRevenue
$11.6 BillionStock Symbol
SDZIndustry
Most Recent Scoops
Jan 13 2025
Hiring Plans
Sandoz has more open roles in Marketing than it has had at any time in the past 9 months. Technologies mentioned include: Kaltura.
Jan 13 2025
Hiring Plans
Sandoz has more open roles in Engineering & Technical than it has had at any time in the past 6 months.
Who is Sandoz
Sandoz, a division of Novartis, produces biosimilars, generic antibiotics and generic oncology medicines. The company offers technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers. Sandoz is headquartered in Holzkirchen, Germany.Explore more
Sandoz Org Chart
Is Sandoz your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sandoz has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Sandoz had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Sandoz
Check out if Sandoz is spiking on competitors!
Sandoz, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sandoz launches new products
Earning: See what the market has to say on Sandoz recently announced quarterly report
Funding: Get notified immidiatlly once Sandoz has new funding data
Recommended Actions
Reach out to Masked Content who joined Sandoz as Masked Content
Find more new buyers
Sandoz Email Formats
Sandoz uses at least 5 email formats with first.last (ex. John.Smith@sandoz.com) being used 74.5% of the time
| Sandoz Email Formats | Percentage | |
|---|---|---|
| first.last | John.Smith@sandoz.com | 74.5% |
| first.last | John.Smith@novartis.com | 2% |
| first + last | JohnSmith@sandoz.com | |
| first_last | John_Smith@sandoz.com | |
| first | John@sandoz.com | |
Get Verified Emails
View Email Formats for Sandoz
Sandoz Employee Growth Rate
View Sandoz’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Sandoz Tech Stack
A closer look at the technologies used by Sandoz
Most Recent Scoops
Jan 13 2025
Hiring Plans
Sandoz has more open roles in Marketing than it has had at any time in the past 9 months. Technologies mentioned include: Kaltura.
Hiring Plans
Jan 13 2025
Hiring Plans
Sandoz has more open roles in Engineering & Technical than it has had at any time in the past 6 months.
Hiring Plans
Jan 10 2025
Hiring Plans
Sandoz has more open roles in Operations than it has had at any time in the past 9 months.
Hiring Plans
Jan 10 2025
Hiring Plans
Sandoz has more open roles in Finance than it has had at any time in the past 9 months.
Hiring Plans
Jan 6 2025
Open Position
Sandoz News & Media
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies’ product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District
Drugmaker Sandoz reaches $275 million settlement to resolve antitrust case - Voz Media
The company does not, however, admit guilt in any of the charges against it, which include price-fixing generic drugs.Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesLoss-making biotech group appoints ex-Sandoz CFO to board - UKTN
London-listed gene therapy company Oxford Biomedica has brought on pharmaceutical executive Colin Bond as a board member.
Read more news
Frequently Asked Questions Regarding Sandoz
Sign Up for FreeTo access detailed company insights
Sandoz, a division of Novartis, produces biosimilars, generic antibiotics and generic oncology medicines. The company offers technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers. Sandoz is headquartered i... Read More
